AMEVIVE® (alefacept) is the first FDA-approved biologic for treatment of moderate-to-severe chronic plaque psoriasis. It works by selectively targeting the T-cells responsible for the disease without disrupting normal immune function. AMEVIVE is indicated for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. For full prescribing information please visit www.Amevive.com.